Background. There is widespread recognition that interventions targeting ''superspreaders'' are more effective at containing epidemics than strategies aimed at the broader population. However, little attention has been devoted to determining optimal levels of coverage for targeted vaccination strategies, given the nonlinear relationship between program scale and the costs and benefits of identifying and successfully administering vaccination to potential superspreaders. Methods. We developed a framework for such an assessment derived from a transmission model of seasonal influenza parameterized to emulate typical seasonal influenza epidemics in the US. We used this framework to estimate how the marginal benefit of expanded targeted vaccination changes with the proportion of the target population already vaccinated. Results. The benefit of targeting additional superspreaders varies considerably as a function of both the baseline vaccination coverage and proximity to the herd immunity threshold. The general form of the marginal benefit function starts low, particularly for severe epidemics, increases monotonically until its peak at the point of herd immunity, and then plummets rapidly. We present a simplified transmission model, primarily designed to convey qualitative insight rather than quantitative precision. With appropriate contact data, future work could address more complex population structures, such as age structure and assortative mixing patterns. Our illustrative example highlights the general economic and epidemiological findings of our method but does not address intervention design, policy, and resource allocation issues related to practical implementation of this particular scenario. Conclusions. Our approach offers a means of estimating willingness to pay for search costs associated with targeted vaccination of superspreaders, which can inform policies regarding whether a targeted intervention should be implemented and, if so, up to what levels. Key words: infectious disease; vaccination; economic analysis; willingness to pay. (Med Decis Making 2014;34:536-549) I n many infectious diseases, individual variation in behavior, infectivity, and contact patterns produces superspreaders responsible for a disproportionate amount of transmission. [1] [2] [3] [4] [5] It has been widely argued that vaccination programs prioritizing potential superspreaders-individuals with characteristics that confer the greatest transmission potential if infected, herein superspreaders-are much more effective than mass vaccination campaigns. 4,6-10 Furthermore, indiscriminate mass vaccination and perfectly targeted superspreader vaccination represent extremes of a continuum between which policy makers could decide on the priority assigned to identification and vaccination of superspreaders. As yet, however, little consideration has been given to determining optimal vaccination coverage in the target population: that is, assessing whether additional costs required to mount or expand a targeted vaccination program are justified by the benefits achieved.
Whereas direct vaccination costs are well known, search costs of finding superspreaders may be difficult to estimate. Search costs, defined here as all additional component costs of a targeted vaccination program, might, for instance, include establishing infrastructure, identifying individuals in the target population, and providing vaccination incentives. These search costs typically increase nonlinearly with the fraction of the target population identified, resulting in diminishing returns to expanding superspreader vaccination. 11 We evaluate circumstances under which targeted vaccination programs should be initiated and how competing considerations might be weighed in determining optimal vaccination coverage levels.
Marginal cost functions for intervention programs vary among diseases and outbreak conditions. While the nature of search costs may preclude the calculation of a marginal cost (MC) function, benefits are more easily quantified. Thus, we can approach the problem from the other side and estimate the marginal benefit (MB) of expanding the intervention. The MB function offers decision makers an upper bound on their willingness to pay for search costs of a targeted vaccination program.
We illustrate this approach in the context of seasonal influenza vaccination of superspreaders. We define superspreaders as individuals with high daily contact rates, and we examine the effect of vaccinating superspreaders upon seasonal influenza epidemic trajectory. Our policy variable of interest is the level of vaccination coverage in the target population (i.e., the percentage of superspreaders vaccinated) and we show how MB is related to this variable. We use this MB function to draw general inferences about both willingness to pay to search for superspreaders and optimal levels of vaccination coverage. Our sensitivity analyses examine the robustness of these findings to changes in input parameters and effectiveness of efforts to identify and vaccinate only superspreaders.
METHODS

Compartmental Model
We describe the effect of influenza superspreader vaccination upon epidemic trajectory and epidemic cost, using a SEIR (Susceptible-Exposed-Infectious-Recovered) compartmental model ( Figure 1 , Table 1) in which individuals can be either vaccinated or unvaccinated and belong to either the superspreader or the ordinary segment of the population. 12 Let S i,j (t), E i,j (t), I i,j (t), and R i,j (t) be the number of susceptible, exposed, infectious, and recovered individuals, respectively, in population segment i (where i = Sup [superspreader] or Ord [ordinary]) having vaccination status j (where j = U [unvaccinated] or V [vaccinated]). We assume that vaccination occurs prior to the influenza season.
Model Parameters
Parameter values reflecting the current state of seasonal influenza in the US were obtained from national datasets and published models ( Table 2) . The baseline vaccination coverage in the population overall is taken to be 31% as per the CDC National Health Interview Survey 20 for both superspreaders, m Sup , and ordinaries, m Ord , in the absence of a targeted vaccination program. In reality, factors such as occupation are likely to be associated with vaccination uptake and with superspreader status defined by daily contact count. These factors may result in different vaccination coverage levels in superspreaders versus ordinaries. However, given that data on vaccination coverage by daily contact count are currently unavailable, we assume equal baseline levels of vaccination in this simplified, stylized model designed to convey qualitative insight rather than quantitative precision. l Sup and l Ord are the force of infection in superspreaders and ordinaries, respectively, given by where b is the probability of transmission given a contact between an infected individual and a susceptible individual. b, in turn, is proportional to the basic reproduction number, R 0 , of the epidemic, defined as the average number of secondary cases resulting from a single primary infection in an otherwise completely susceptible population. For the baseline analysis, we assume R 0 = 1.6 and we perform sensitivity 19 providing age and number of daily contacts for 7225 individuals. For purposes of illustration we chose a superspreader/ordinary definition threshold (S/O threshold) of 20%, defining superspreaders as the 20% of the population with the highest daily contact rates. Although 20% is somewhat arbitrary, it has been extensively observed for myriad disease 1, [3] [4] [5] [6] 27 and other systems 28 that a high proportion of an effect or activity, such as transmission, is attributable to 20% of the population, the so-called Pareto principle. Following this principle, the top 20% (N Sup = 200,000) of observations in our sampled population, ordered by contact count, became the superspreader segment of the population and the remainder the ordinary population (N Ord = 800,000) (online appendix Figure A1 , Panel A). In this parameterization, superspreaders are responsible for 46.6% of all daily contacts (online appendix Figure A1 , Panel B). Mean contact rates per day were calculated for superspreaders and ordinaries, and, assuming random contact formation between superspreaders and ordinaries, probabilities of each type of contact were calculated. (Further discussion of the definition of superspreaders using the Pareto principle, resultant model population structure, and full details of calculations made to fit b and to obtain final contact matrix values are included in the online appendix.)
Although superspreading-skewed distribution of transmission potential in the population-can result from a combination of behavior, susceptibility, infectivity, and contact patterns, these factors are subsumed in the product of the contact rates (f i,j ) and probability of transmission (b). If superspreading were modeled using differences in individual infectivity instead of contact rates, the same force of infection could result from an equivalent distribution of transmission potential simulated using varied probabilities of infection acquisition and/or transmission per contact (higher for superspreaders, lower for ordinaries), in a homogeneously mixing population with contact rate fitted to give the desired R 0 . Thus, the two parameterizations would be numerically equivalent and model findings would be unaffected. The same can be said of parameterizations that lie between these extremes and attribute superspreading to combined differences in both contact rates and infectivity. 
Intervention Parameters
Vaccine efficacy. The efficacy of the vaccine in preventing infection is e: That is, we define vaccine efficacy as a percentage reduction in probability of transmission per contact, ranging between 0% (no efficacy) and 100% (perfect efficacy) ( Figure 1 ). The efficacy of the influenza vaccine in preventing infection across all ages of individuals (77.4%) is calculated as a weighted average of estimates for particular age groups (80% for age \65, 16, 17 60% for age !65 18 ) using the US population age distribution in 2009. 29 Influenza-induced death rates for unvaccinated and vaccinated individuals are also calculated as weighted averages of age-specific estimates. 16 Vaccination targeting effectiveness. Vaccination targeting effectiveness (r) is defined as how well the vaccination program identifies and vaccinates only superspreaders versus imperfectly targeting superspreaders and thus simultaneously increasing the vaccination coverage in the ordinary segment of the population to the same or lesser extent. Perfectly targeted vaccination (targeting effectiveness, r = 1) is compared with indiscriminate mass vaccination (targeting effectiveness, r = 0).
For example, with a baseline level of vaccination in the population (B) of 31% and an intervention size in the superspreader population (i) of 10%, the intervention increases vaccination coverage in superspreaders (m Sup , our policy variable of interest) from 31% to 41%. With perfect vaccination targeting effectiveness, r = 1, m Sup = (B 1 i) = 41%, and m Ord = (B 1 i(1 -r)) = 31%; the intervention vaccinates N Sup *i = 20,000 individuals, all of whom are superspreaders. With mass vaccination, r = 0, m Sup = (B 1 i) = 41%, and m Ord = (B 1 i(1 -r)) = 41%; the intervention vaccinates 100,000 individuals, of whom N Sup *i = 20,000 are superspreaders and N Ord *i(1 -r) = 80,000 are ordinaries; the proportion of intervention vaccinations going to superspreaders (20%) equals the proportion of superspreaders in the population.
Costs. Vaccinating superspreaders incurs search costs and vaccination costs. Benefits (equivalently, cost savings) result from infections, hospitalizations, and deaths averted. To provide an MB function directly comparable to the marginal search cost function, we subtract known per-person costs of vaccination from cost savings associated with health benefits resulting from additional vaccinations. Thus, measurable costs and benefits are captured within MB = (cost savings -vaccination costs), which informs decision makers specifically about their willingness to pay for the search costs of a targeted vaccination program.
Consistent with previous influenza models, costs included are those associated with vaccination itself, infection (assumed more severe, and hence costly, for unvaccinated than vaccinated infected individuals), and mortality 15, 16 (Table 3) . Age-specific cost estimates for infection (vaccinated and unvaccinated) and illness-related medical care prior to death 12 are each weighted according to the US population in 2009 29 to give a single cost per event. Vaccination cost includes costs of vaccine, travel, work time lost, and weighted adverse event costs. 15, 16 Infection costs are calculated from weighted probabilities and costs of hospitalizations, outpatient visits, work days lost, and over-the-counter medications. 16 Cost of death includes hospitalization and indirect costs calculated using present value of lifetime earnings lost. 16 Costs are expressed in 2010 USD, calculated using the consumer price index. 31 
Baseline Analysis: Perfectly Targeted Vaccination
In the baseline analysis (Table 2) , we assumed perfect vaccination targeting effectiveness (r = 1), vaccine efficacy (e) of 77.4%, and 31% vaccination coverage of ordinaries. We considered vaccination coverage in the superspreader population (m Sup ) ranging from 31% to 100%. Event counts (number of vaccinations, infections in unvaccinated and vaccinated individuals, deaths) were multiplied by their associated costs to give a total cost for each epidemic. MB per additional superspreader vaccinated was calculated as follows:
We explored the robustness of the MB function to epidemiological and cost input data uncertainty by conducting deterministic 1-and 2-way sensitivity analyses on the model parameters (Tables 2 and 3 ). The relative impact of uncertainty across input parameters was compared using spider plots. Model structure sensitivity analyses (in the online appendix) describe the effects upon our results of the choice of S/O definition threshold and of variation in underlying population contact count distribution.
Perfectly Targeted Versus Mass Vaccination
To compare targeted (r = 1) and mass (r = 0) vaccination programs, initial vaccination coverage in the population was assumed to be 0%. For perfectly targeted vaccination, vaccination coverage of ordinaries (m Ord ) remained 0%, and we considered vaccination coverage of superspreaders (m Sup ) from 0% to 100%. For mass vaccination, vaccination coverages of ordinaries and superspreaders were increased simultaneously (m Sup and m Ord from 0% to 100%). Total epidemic costs were calculated as described previously and MB was calculated per additional individual vaccinated. Indiscriminate mass vaccination is equivalent to the extreme case of imperfectly targeted vaccination. For mass vaccination, the intervention fails to preferentially identify and vaccinate superspreaders over ordinaries and vaccinates each group at the rate that would be achieved by random selection of individuals from the population. Thus, by considering targeted and mass vaccination programs, we describe ends of the spectrum, between which imperfectly targeted interventions would lie.
RESULTS
Baseline Analysis: Perfectly Targeted Vaccination
The largest cost component is mortality, followed by cost of infection to unvaccinated individuals (Figure 2) . Costs of life lost, hospital care prior to death, and infections all decrease with higher vaccination coverage, whereas vaccination costs increase. MB is positive at baseline and, at first, increases monotonically with higher vaccination coverage of superspreaders. This reflects larger proportional reductions in both epidemic size and costs achieved with increasing coverage of superspreaders. MB peaks when herd immunity is achieved. At even higher levels of vaccination coverage, MB plummets rapidly, remaining positive while additional vaccination accelerates extinction of the initial infection and becoming negative when no additional epidemiological benefit is acquired from further vaccination (Figure 2) .
The MB function has 3 key points: (1) value at baseline (y-intercept): the MB for identification and vaccination of the first superspreader post baseline; (2) peak MB: MB for the identification and vaccination of the last superspreader prior to achieving herd immunity in the population; and (3) percentage of superspreaders vaccinated at peak MB: the vaccination coverage of superspreaders necessary to achieve herd immunity.
The shapes of epidemic cost and MB functions are robust across all values of R 0 where transmission is sustained in the population. Total epidemic costs and vaccination coverage of superspreaders necessary to achieve herd immunity both increase with rising R 0 (Figure 3) . At higher levels of R 0 , the MB function adopts a lower baseline value but rises to a higher peak.
Epidemic cost and MB functions exhibit similar behaviors in scenarios with more narrowly or widely defined superspreader populations and varied degrees of contact rate heterogeneity. (See model structure sensitivity analyses in the online appendix, Figures A1 to A4) .
Spider plots illustrate sensitivity of the key points of the MB function to parameter uncertainty (Figure 4 ). Both baseline MB (Figure 4 , top panel) and peak MB (Figure 4 , middle panel) increase with vaccine efficacy (e), value of life lost (e), mortality rate in the unvaccinated (y U ), and mortality rates overall (y U and y V together). Baseline MB and peak MB are relatively insensitive to changes in mortality rate in the vaccinated (y V ), cost of illness-related care prior to death (d), costs of infection (b and c, all showing slight positive relationships), and vaccination cost (a) (slight negative relationship). Variations in incubation period (t), have no effect upon baseline MB and a slight negative effect upon peak MB. A lower recovery rate (g) reduces baseline MB and increases peak MB.
Perfectly Targeted Versus Mass Vaccination
Under a targeted vaccination program, for any value of R 0 , total epidemic cost declines more quickly than under a mass or imperfectly targeted vaccination program ( Figure 5 , top). MB is higher at baseline, increases more steeply, and peaks higher for a targeted versus a mass vaccination program ( Figure 5 , bottom).
Herd immunity is achieved by vaccinating a far smaller proportion of the population using targeted superspreader vaccination versus mass vaccination ( Figures 5 and 6 ).
Equating Marginal Benefit and Marginal Cost
Our interest in any specific MB function is twofold. The height of the MB describes absolute willingness to pay for search costs, assuming we require positive net benefit to implement the vaccination program. The intersection of MB with an MC function-after which MC becomes greater than MB-indicates the level of vaccination coverage in the targeted population that maximizes net benefit (total incremental benefit minus total incremental cost). Given that the form of the MB function is robust to variation in model parameters, we can consider its standard shape and implications for intersection with possible MC functions.
Assuming decreasing returns to investment in search costs, we can envisage some potential functional forms for an MC function (Figure 7 ). If cost were to depend upon percentage of superspreaders already identified and vaccinated, MC would be linear, monotonically increasing, for example, where x is the percentage of vaccination coverage in superspreaders, MC 1 = cx ( Figure 7A ). Alternatively, if cost were to be inversely proportional to percentage of superspreaders currently remaining unidentified and unvaccinated, MC would be hyperbolic, monotonically increasing, for example, MC 2 = c/ (100 -x) ( Figure 7B ).
If we subsequently consider the possibility that there is some fixed cost to the intervention (infrastructure, setup costs, etc.), we have an additional cost component that decreases (marginally) with identification and vaccination of increasing numbers of superspreaders, as the fixed cost is spread across more individuals. This function would be hyperbolic, monotonically decreasing, for example, MC = k/x. Summing this fixed MC component with our original functions would give us J-and U-shaped cost functions: MC 3 = cx 1 k/x ( Figure 7C) and Figure 7D ), respectively.
The 4 MB-MC intersection scenarios are consistent across the potential functional forms that we consider for MC (Figure 7 , second column): (I) MC is greater than MB at baseline and remains consistently higher than MB; thus, MB and MC do not intersect. (II) MC is less than MB at baseline, increases steeply, and intersects the top section of the MB curve. (III) MC is less than MB at baseline and increases relatively shallowly. (IV) MC is greater than MB at baseline, drops to cross MB, and then subsequently intersects MB again in either its top section or at or slightly above herd immunity. For scenario I, the net benefit of intervention is negative at any level of vaccination Figure 5 Sensitivity of total epidemic cost, marginal benefit, and herd immunity to R 0 in perfectly targeted versus mass vaccination strategies. Vertical lines, peak marginal benefit/herd immunity. Heavy lines, perfectly targeted strategy. Lighter lines, mass strategy. Online appendix Figure A6 shows all R 0 values from 1.0 to 2.5. Baseline vaccination coverage of superspreaders and ordinaries is 0% (v. 31% in the analysis presented in Figure 3 ). coverage of superspreaders, it would not be optimal to devote any resources to targeting vaccination to superspreaders, and therefore the vaccination program would not be implemented. For II and III, the net benefit is positive and is maximized by choosing the level of vaccination coverage of superspreaders where MB and MC intersect. Under scenario IV, net benefit is maximized at the second MB-MC intersection but may be positive-in which case the level of vaccination coverage of superspreaders at the second MB-MC intersection would be optimal-or negative, in which case the vaccination program would not be implemented.
DISCUSSION
Economic and Epidemiologic Results
Our model informs the assessment of optimal levels of vaccination coverage for targeted vaccination programs, given nonlinear cost and benefit functions for identifying and administering vaccination to superspreaders. It offers decision makers an upper bound on the willingness to pay to identify and vaccinate additional superspreaders by estimating how the MB of expanded targeted influenza vaccination changes with the proportion of the population already vaccinated.
This approach can determine whether a targeted vaccination program should be initiated based on its cost-effectiveness and, if so, to what levels, and to compare the marginal benefits of vaccinating superspreaders to indiscriminate mass vaccination. Considering several reasonable functional forms for search costs in conjunction with the MB function, we found that when targeted superspreader vaccination offers economic benefit, optimal vaccination coverage is often at or slightly above that required to achieve herd immunity.
Increasing superspreader vaccination dramatically reduces epidemic size and thus epidemic cost. Cost decomposition reveals that total epidemic cost is dominated by value ascribed to life lost and costs of infection to unvaccinated individuals. Given that MB is derived from cost savings accrued as epidemic size and cost both decrease, the MB function is similarly dominated by these two cost components. For a perfectly targeted superspreader vaccination program, MB can be considered as the dollar benefit gained or, equivalently, the dollar cost saved per additional superspreader vaccinated. For an Figure 7 Intersection of marginal benefit with marginal cost functions. (I) Net benefit of intervention is negative at any level of vaccination coverage of superspreaders; therefore, it would not be optimal to devote resources to targeted vaccination and the vaccination program would not be implemented. (II & III) Net benefit is positive and is maximized by choosing the level of vaccination coverage of superspreaders where MB and MC intersect. (IV) Net benefit is maximized at the second MB-MC intersection: If net benefit is positive, the level of vaccination coverage of superspreaders at the second MB-MC intersection is optimal; if net benefit is negative, the vaccination program would not be implemented.
imperfectly targeted vaccination program, these measures are per additional individual vaccinated.
The requirement of positive net benefit for superspreader vaccination means MB can be thought of as a maximum willingness to pay per additional superspreader vaccinated. This criterion is conservative as interventions that are cost-effective, and not merely cost-neutral or cost-saving, are often accepted. 32 While we ascribe a cost to life lost based on value of lifetime earnings, this underestimates the value that most individuals and economists place on lives lost. Infection costs would also be greater if morbidity was valued explicitly. Relaxing the assumption of requiring positive net benefit would allow levels of program implementation beyond that associated with maximum net benefit to be considered.
The likelihood that MB will be higher than MC depends on the absolute values of the MB function and thus is primarily affected by the magnitude of medical care costs and value of life lost. When vaccine efficacy is relatively high, the majority of infections and deaths occur in the unvaccinated population. Thus, the mortality rate in unvaccinated individuals drives the majority of the infection costs and death costs, and a higher mortality rate in unvaccinated individuals results in higher MB. There are comparatively fewer deaths among vaccinated individuals. In these persons, the impact of a higher mortality rate on MB is still positive but relatively smaller.
Epidemics with higher R 0 values incur greater total costs; consequently, total willingness to pay for targeting superspreaders is greater for a more severe epidemic. Higher R 0 also results in lower baseline MB and higher peak MB, because in a more severe epidemic vaccinating the first superspreader has relatively little impact, whereas the impact of vaccinating the final superspreader necessary to achieve herd immunity and prevent an outbreak altogether is dramatic.
From a public health perspective, targeting highcontact superspreaders will generally produce greatest economic benefit when intervention significantly reduces transmission potential, for diseases possessing characteristics conducive to large, costly epidemics (high R 0 , high probability of transmission [b], long infectious period, high costs of morbidity and mortality relative to intervention), and when infectiousness does not incapacitate in a manner that negates contact formation.
In a perfectly targeted vaccination program, total epidemic cost declines more quickly with proportion of total population vaccinated, MB per individual identified and vaccinated is substantially higher, and herd immunity is achieved via vaccinating a smaller proportion of the population than in imperfectly targeted or mass vaccination. A decision maker choosing between vaccination strategies-given an approximate sense of search costs associated with identification and vaccination of superspreaders versus individuals at random-can equate the targeted and mass MB functions, calculated using our approach, with their respective search cost functions. The resulting estimates of optimal vaccination coverage levels and corresponding net benefits/costs for targeted and mass vaccination programs can be compared to select the vaccination strategy with greater net benefit or lower net cost. Assuming search costs are zero for mass vaccination, MB is close to net benefit, and optimal vaccination coverage occurs where net benefit goes to zero, slightly above herd immunity.
Strengths, Limitations, and Practical Application
Our illustrative example provides a template to inform the assessment of potential targeted interventions from an economic perspective. Our analysis is not intended as a complete or quantitatively precise description of a program of seasonal influenza vaccination of high-contact individuals in the US or as a prescription for the implementation of such an intervention. For a decision maker undertaking a similar analysis, useful results will require careful model construction to ensure an accurate representation of the relevant population, disease, and intervention mechanism.
Targeted intervention is feasible-and, presumably, undertaking an economic assessment is of value-where processes and resources exist to successfully identify and administer the intervention to a defined population of superspreaders, within a time frame that matches the nature of the disease and the intervention.
Targeting high-contact individuals for vaccination is a plausible and generalizable strategy, lending strength to both our approach and our example. Of the individual-level characteristics contributing to superspreading-behavior, susceptibility, infectivity, and contact patterns-high contact rate can be assessed relatively easily and in the absence of infection, allowing a priori identification and effective vaccination of potential superspreaders. Furthermore, although targeted vaccination of superspreaders, defined only by high contact rate, does not necessarily capture all individuals who may be potential superspreaders due to other characteristics-risky behaviors, high susceptibility, high infectivity-the intervention still addresses a disproportionate part of the transmission by capturing individuals whose high transmission potential results from the synergistic combination of those characteristics and the highest contact rates. [1] [2] [3] [4] 33, 34 Many approaches could be used to identify and vaccinate high-contact individuals. Acquaintance vaccination is one established method, relying on the concept that randomly selected contacts of randomly selected individuals are, on average, more highly connected than the initial set of individuals. 3, 4, 6, 10, [34] [35] [36] Identification could also use selfreported contact rate, or demographic measures correlated with high contact rate, such as age group (school children 12, 37, 38 ), profession (teachers or health care professionals, 34, 39 high-frequency short-duration service professions such as sales clerks and wait staff), geography (urban v. rural), or certain activities or behaviors (commuting via public transport, participation in mass gatherings, 40 airline travel 41 ).
Administration of vaccination to high-contact individuals might involve primary care providers; vaccination in schools, workplaces, or public venues; educational campaigns; and/or provision of incentives to encourage vaccination uptake. Ultimately, decision makers must determine a set of identification and vaccination administration strategies compatible with their target populations and available resources.
Any model, as an abstraction of reality intended to provide useful and relevant results, faces tradeoffs between simplicity of construction, parameterization, analysis, and interpretation and the accuracy with which it captures real-world dynamics.
We model intervention and population parsimoniously, using a traditional compartmental representation of population, disease, and vaccination dynamics. This entails standard assumptions: homogeneity within each compartment, with all individuals ascribed identical properties equal to the mean of the property in that population segment; and random mixing of individuals in the population, subject to the contact matrix structure. These simplifications collapse continuously distributed population characteristics into discrete distributions or single values. While this gradation is suitable for certain attributes, the loss of more nuanced behavior is a potential limitation.
Binary superspreader/ordinary classification is the simplest basis for targeted intervention, requiring only assessment of individuals' daily contact counts relative to the chosen S/O threshold to determine superspreader status. Our model stratification corresponds to this classification and provides a realistic assessment of the results that can be expected when applying a particular superspreader population definition (S/O threshold) and establishing a level of vaccination coverage in that population. In addition, the vaccination targeting effectiveness parameter facilitates exploration of potential effects of identification and vaccination administration strategies, such as those mentioned above, having imperfect sensitivity and specificity.
We examined the sensitivity of the MB function, varying one model parameter input at a time across a broad range of plausible values. In practice, when applying our approach to a particular epidemic and intervention program, many inputs could be specified with reasonable precision and the effect of correlation between inputs explored. Estimates of R 0 -which has a key role in shaping the MB function-may remain uncertain at the time an intervention is planned. Nevertheless, we have demonstrated that it is straightforward to generate a family of MB functions that could be considered in the decision-making process.
Model structure sensitivity analyses provide confidence in the generalizability of our primary epidemic cost and MB findings and illuminate issues pertinent to selecting appropriate levels of complexity as a basis for intervention and for modeling intervention and population dynamics (online appendix).
Targeted intervention is, naturally, ineffective in homogeneous populations and is of limited benefit in populations with contact distributions skewed to the extent that the superspreader population becomes self-isolating; thus, the greatest benefits accrue in populations with contact rate heterogeneity between these extremes. Selecting a lower S/O threshold will yield a superspreader population for which vaccination is of greater effectiveness in reducing the epidemic overall. However, the greater MB of those vaccinations is likely to be accompanied by greater marginal search costs of finding these superspreaders-fewer in absolute number and possessing contact rates further from the population mean-and decreased intervention targeting effectiveness may result.
The ideal level of complexity for the model population structure is an open question. Certain artifacts resulting from abstraction of population dynamics are seen in the model structure sensitivity analyses and are discussed in detail in the online appendix. Simulation accuracy may be improved by increasing the level of modeling complexity for the population while retaining the binary classification basis for intervention: selecting the average individual from the model strata comprised of superspreaders. Given age-specific incidence patterns of relevant diseases, the model could be extended to capture more complex population dynamics via stratification by age and exploration of assortative mixing patterns by age groups and/or superspreader status.
Decision makers require estimates of the contact distribution in their population of interest to make an informed assessment regarding appropriate intervention and modeling strategies and to select a practical and effective S/O threshold. Furthermore, the feasibility and utility of more complex models require sufficient data regarding epidemiological parameters, intervention efficacy, and known morbidity, mortality, and intervention costs, as well as detailed contact distribution data, including both age and daily contact count for each individual and for his or her respective contacts. Detailed surveys of contact patterns 19, 38 aid identification of highcontact demographics and may need to be conducted within the population of interest. If data required to parameterize a more complex model population structure are available, a targeting strategy using additional strata may also be feasible and will be more effective in terms of achieving herd immunity with a minimum number of vaccinations.
CONCLUSION
Targeted vaccination of superspreaders is more effective in reducing total epidemic size and cost and achieves herd immunity with fewer vaccine doses than a mass strategy. However, these benefits should be weighed in conjunction with the search costs fundamental to superspreader vaccination. Using seasonal influenza as an illustrative example, we have shown how an MB function can be produced to aid decision making regarding implementation of a targeted vaccination program and selection of optimal vaccination coverage levels. Comparing MB functions for targeted versus mass vaccination programs, our calculations indicate that willingness to pay for the identification and vaccination of superspreaders is considerably higher than our willingness to pay for the vaccination of individuals at random. Considering hypothetical cost functions, we found that when targeted superspreader vaccination offers economic benefit, it is worth implementing at maximum only up to, or slightly above, the vaccination coverage required to achieve herd immunity. Effectively targeting superspreaders makes vaccination of substantial proportions of the population unnecessary due to the indirect protection from infection afforded by herd immunity.
